146 related articles for article (PubMed ID: 30601319)
81. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study.
Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D
Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980
[TBL] [Abstract][Full Text] [Related]
82. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community.
Egido JJ; Gomez R; Romero SP; Andrey JL; Ramirez D; Rodriguez A; Pedrosa MJ; Gomez F
Int J Clin Pract; 2019 Jun; 73(6):e13317. PubMed ID: 30694579
[TBL] [Abstract][Full Text] [Related]
83. Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review.
AlRuthia Y; Alotaibi F; Jamal A; Sales I; Alwhaibi M; Alqahtani N; AlNajrany SM; Almalki K; Alsaigh A; Mansy W
Healthcare (Basel); 2021 Jun; 9(7):. PubMed ID: 34202109
[TBL] [Abstract][Full Text] [Related]
84. Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis.
Akazawa M; Fukuoka K
BMC Health Serv Res; 2013 Apr; 13():124. PubMed ID: 23552327
[TBL] [Abstract][Full Text] [Related]
85. Need to revisit step therapy for ARBs.
Ram CV; Giles T
J Manag Care Pharm; 2007; 13(6):528-9; author reply 529; discussion 529-31. PubMed ID: 17672815
[No Abstract] [Full Text] [Related]
86. The uses and expenses of antihypertensive medications among hypertensive adults.
Park C; Wang G; Ng BP; Fang J; Durthaler JM; Ayala C
Res Social Adm Pharm; 2020 Feb; 16(2):183-189. PubMed ID: 31085142
[TBL] [Abstract][Full Text] [Related]
87. Effectiveness of treatment of newly diagnosed hypertension in family medicine practices in South Croatia.
Jurić D; Pavličević I; Marušić A; Malički M; Buljan I; Šarotić V; Mrduljaš-Đujić N; Komparak A; Vujević M; De Micheli-Vitturi D; Šušnjar P; Puljiz T; Jerčić M; Leskur D; Marušić M
BMC Fam Pract; 2019 Jan; 20(1):10. PubMed ID: 30642264
[TBL] [Abstract][Full Text] [Related]
88. Withholding vs. Continuing Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Before Non-cardiac Surgery in Older Patients: Study Protocol for a Multicenter Randomized Controlled Trial.
Yang YF; Zhu YJ; Long YQ; Liu HY; Shan XS; Feng XM; Peng K; Ji FH
Front Med (Lausanne); 2021; 8():654700. PubMed ID: 33859991
[No Abstract] [Full Text] [Related]
89. A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Hedenmalm K; Quinten C; Kurz X; Bradley M; Lee H; Eworuke E
Eur J Clin Pharmacol; 2023 Jun; 79(6):849-858. PubMed ID: 37095262
[TBL] [Abstract][Full Text] [Related]
90. Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage.
Zhang C; Zhong J; Chen WX; Zhang XY; Li YH; Zhou TY; Zou YJ; Lan C; Li L; Lai ZP; Feng H; Hu R
Neuropsychiatr Dis Treat; 2021; 17():355-363. PubMed ID: 33603374
[TBL] [Abstract][Full Text] [Related]
91. Medication adherence and associated factors in newly diagnosed hypertensive patients in Japan: the LIFE study.
Sagara K; Goto K; Maeda M; Murata F; Fukuda H
J Hypertens; 2024 Apr; 42(4):718-726. PubMed ID: 38230627
[TBL] [Abstract][Full Text] [Related]
92. Management of Hypertension in the Asia-Pacific Region: A Structured Review.
Rahman ARA; Magno JDA; Cai J; Han M; Lee HY; Nair T; Narayan O; Panyapat J; Van Minh H; Khurana R
Am J Cardiovasc Drugs; 2024 Mar; 24(2):141-170. PubMed ID: 38332411
[TBL] [Abstract][Full Text] [Related]
93. Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media.
Micale C; Golder S; O'Connor K; Weissenbacher D; Gross R; Hennessy S; Gonzalez-Hernandez G
Drug Saf; 2024 Jan; 47(1):81-91. PubMed ID: 37995049
[TBL] [Abstract][Full Text] [Related]
94. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study.
Hicks BM; Filion KB; Yin H; Sakr L; Udell JA; Azoulay L
BMJ; 2018 Oct; 363():k4209. PubMed ID: 30355745
[TBL] [Abstract][Full Text] [Related]
95. The impact of Medicare Part D on medication treatment of hypertension.
Zhang Y; Donohue JM; Lave JR; Gellad WF
Health Serv Res; 2011 Feb; 46(1 Pt 1):185-98. PubMed ID: 20880045
[TBL] [Abstract][Full Text] [Related]
96. The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis.
Laba TL; Worthington HC; Cheng L; Chan FKI; Bansback N; Law MR
CMAJ Open; 2022; 10(4):E1059-E1066. PubMed ID: 36735223
[TBL] [Abstract][Full Text] [Related]
97. Outcomes of sword swallowing and pharmaceutical step-therapy interventions.
Curtiss FR
J Manag Care Pharm; 2007 Apr; 13(3):284-6. PubMed ID: 17407396
[No Abstract] [Full Text] [Related]
98. Drugs Becoming Generics-The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients.
Kovács B; Darida M; Simon J
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574353
[TBL] [Abstract][Full Text] [Related]
99. Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis.
Mansfield KE; Douglas IJ; Nitsch D; Thomas SL; Smeeth L; Tomlinson LA
Clin Epidemiol; 2018; 10():187-202. PubMed ID: 29430198
[TBL] [Abstract][Full Text] [Related]
100. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians.
Shinohara Y; Origasa H
Adv Ther; 2012 Oct; 29(10):900-12. PubMed ID: 22983755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
